KORU Medical Systems (NASDAQ:KRMD) Downgraded by Wall Street Zen to “Buy”

KORU Medical Systems (NASDAQ:KRMD) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Sunday.

A number of other equities analysts have also weighed in on KRMD. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Wednesday, October 8th. Lake Street Capital boosted their price target on shares of KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Finally, Canaccord Genuity Group upped their price objective on shares of KORU Medical Systems from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, KORU Medical Systems presently has an average rating of “Moderate Buy” and an average price target of $5.88.

KORU Medical Systems Stock Performance

KRMD opened at $5.61 on Friday. The business has a 50 day moving average of $5.13 and a 200-day moving average of $4.29. KORU Medical Systems has a 12-month low of $1.86 and a 12-month high of $6.61. The company has a quick ratio of 1.92, a current ratio of 2.48 and a debt-to-equity ratio of 0.01. The stock has a market cap of $259.86 million, a price-to-earnings ratio of -70.13 and a beta of 0.51.

Institutional Investors Weigh In On KORU Medical Systems

Several institutional investors have recently bought and sold shares of KRMD. First Light Asset Management LLC raised its position in KORU Medical Systems by 5.1% in the 2nd quarter. First Light Asset Management LLC now owns 4,681,626 shares of the company’s stock valued at $16,760,000 after buying an additional 226,700 shares during the last quarter. Topline Capital Management LLC grew its stake in shares of KORU Medical Systems by 1.1% in the 3rd quarter. Topline Capital Management LLC now owns 3,648,240 shares of the company’s stock worth $13,973,000 after acquiring an additional 39,893 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of KORU Medical Systems by 2.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,145,772 shares of the company’s stock worth $8,218,000 after acquiring an additional 60,109 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of KORU Medical Systems by 101.3% in the second quarter. Geode Capital Management LLC now owns 997,147 shares of the company’s stock valued at $3,571,000 after purchasing an additional 501,875 shares during the last quarter. Finally, Acuitas Investments LLC lifted its position in shares of KORU Medical Systems by 89.6% during the third quarter. Acuitas Investments LLC now owns 763,088 shares of the company’s stock valued at $2,923,000 after purchasing an additional 360,594 shares in the last quarter. Institutional investors own 58.60% of the company’s stock.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.